Prospector Partners’s GSK GSK Stock Holding History

Prospector Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-110,720	Closed	-$5.56M	–	113
2018 Q3	$5.56M	Buy	110,720 +1,360	+1%	+$69.1K	0.77%	52
2018 Q2	$5.51M	Sell	109,360 -880	-0.8%	-$44.3K	0.77%	54
2018 Q1	$5.38M	Sell	110,240 -1,920	-2%	-$89.4K	0.79%	54
2017 Q4	$4.97M	Sell	112,160 -9,680	-8%	-$447K	0.73%	50
2017 Q3	$6.18M	Sell	121,840 -2,240	-2%	-$114K	0.94%	43
2017 Q2	$6.69M	Sell	124,080 -4,560	-4%	-$243K	1.05%	36
2017 Q1	$6.78M	Sell	128,640 -320	-0.2%	-$16.2K	1.04%	36
2016 Q4	$6.21M	Buy	128,960 +113,920	+757%	+$5.63M	0.92%	40
2016 Q3	$811K	Hold	15,040	–	–	0.13%	124
2016 Q2	$815K	Hold	15,040	–	–	0.14%	119
2016 Q1	$762K	Hold	15,040	–	–	0.13%	116
2015 Q4	$759K	Sell	15,040 -49,280	-77%	-$2.51M	0.14%	113
2015 Q3	$3.09M	Buy	64,320 +2,080	+3%	+$108K	0.45%	76
2015 Q2	$3.24M	Sell	62,240 -187,440	-75%	-$10.6M	0.38%	73
2015 Q1	$14.4M	Hold	249,680	–	–	1.08%	31
2014 Q4	$13.3M	Buy	+249,680	New	+$14M	1.01%	30

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Prospector Partners's GSK Position: Q4 2018 in Review

Prospector Partners sold out of GSK (GSK) in Q4 2018, closing a stake of 110,720 shares — an estimated $5.56M sold.

Prospector Partners first reported a position in GSK in Q4 2014 and held it in 16 quarters. The position peaked at $14.4M in Q1 2015. 799 funds tracked by Wall St. Rank hold GSK as of Q4 2018.

Prospector Partners reported no remaining GSK position as of Q4 2018 after selling out during the quarter.
Prospector Partners sold 110,720 GSK shares in Q4 2018, an estimated $5.56M.
Prospector Partners first reported a position in GSK in Q4 2014 and held it in 16 quarters.
Prospector Partners's GSK position peaked at $14.4M in Q1 2015.
799 funds tracked by Wall St. Rank held GSK as of Q4 2018.

Based on Prospector Partners's 13F filing for Q4 2018, filed 14 Feb 2019.